PrairieGold Venture Partners is a venture capital firm located in Sioux Falls, South Dakota, that focuses on early-stage investments. The firm specializes in sectors such as life sciences, green technology, information technology, and alternative energy. PrairieGold typically invests between $0.25 million and $2 million in companies, with transaction sizes ranging from $0.25 million to $10 million. The firm aims to support companies in the Midwest region and often seeks a board seat in its portfolio companies to provide guidance and oversight.
Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.
Chronix Biomedical
Series B in 2008
Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.